United Kingdom Archives

More News! 19 Sep 2017

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

Scientists in Scotland claim gene expression in the brain is so precisely controlled that they could predict your age just by looking at your genome. Researchers at the University of Edinburgh believe that genes in the brain are expressed at very specific times during a person’s life to carry out particular functions. Changes were seen […]

September 19, 2017 - 2 minutesmins - By Alex Dale

News and Trends 18 Sep 2017

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation have injected $40M (€33M) into Immunocore to accelerate the development of its immunotherapies for infectious diseases. Investment from the Bill & Melinda Gates Foundation will support the development of Immunocore’s ImmTAV and ImmTAB TCR-based technologies, which help the immune system to target virally and bacterially infected cells, respectively. In particular, […]

September 18, 2017 - 2 minutesmins - By Alex Dale

News and Trends 18 Sep 2017

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Allergy Therapeutics’ vaccine against hayfever has received approval to begin a trial to determine its optimal dose. Allergy Therapeutics will begin a Phase II trial of its PQ Grass vaccine for grass pollen-induced allergic rhinitis imminently. A major selling point for PQ Grass is its ultra-short course, which reduces treatment time from 1 year to […]

September 18, 2017 - 2 minutesmins - By Alex Dale

News and Trends 15 Sep 2017

New British Biotech Enters the Clinic with Opioid Alternative for Chronic Pain

Levicept’s Phase I study will test their new pain relief candidate’s safety and tolerability in healthy individuals and osteoarthritis patients. Levicept, based in Sandwich, UK, focuses on the development of its pain relief candidate, LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc). The Phase I study is the company’s maiden voyage into the clinic, and it will test the […]

September 15, 2017 - 3 minutesmins - By Alex Dale

More News! 14 Sep 2017

Could Using Bacteria’s Own Killing Capacity be a Knockout Blow in the Fight Against Antibiotic Resistance?

Scientists in the UK and US have identified how in-fighting between bacteria could provide a new treatment for hospital-acquired infections. Clostridium difficile is a common cause of hospital-acquired infections, which kill almost 4,000 people in Europe each year. Scientists at the University of Sheffield, the University of Glasgow, and California-based biotech AvidBiotics Corp have discovered that C. difficile uses nanomolecular […]

September 14, 2017 - 2 minutesmins - By Alex Dale

News and Trends 12 Sep 2017

British Biotech Receives €52M Boost To Beat Antimicrobial Resistance with New Antibiotic

Summit Therapeutics has been awarded the Barda Contract worth up to $62M (€52M) to continue to the development of a new antibiotic for hospital-acquired infections. Summit Therapeutics, a biopharma company operating in the UK and US, has received the Barda Contract, designed to counter public health emergencies. In this case, the money will help to […]

September 12, 2017 - 3 minutesmins - By Alex Dale

News and Trends 8 Sep 2017

GSK wants in on Adaptimmune’s Adaptable T cell Cancer Treatment

GSK has backed Adaptimmune in the development of their adaptable NY-ESO SPEAR T cell cancer therapy, causing an 11% jump in their premarket value. Adaptimmune has received support from GlaxoSmithKline (GSK) for the development of their NY-ESO SPEAR T cell, which will hopefully treat a range of different cancers. The British pharma giant will pay milestones of up to £48M (€52M) […]

September 8, 2017 - 2 minutesmins - By Alex Dale

News and Trends 7 Sep 2017

Scottish Oncology Biotech Aims for €96M IPO in the Nasdaq

Nucana Biomed has filed for a Nasdaq IPO in which it expects to raise up to $115M (€96M) to support the progression of its oncology pipeline. Nucana Biomed, a biotech based in Edinburgh, specializes in using phosphoramidate chemistry to upgrade nucleoside analogs, a common form of chemotherapy drugs. With its pipeline reaching late stages of […]

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Sep 2017

Verona Achieves Successful Results for Phase IIa Trial of Deadly Lung Disease Drug

A study of Verona’s combination therapy for COPD observed a clinical improvement in lung function and faster onset-of-action. Verona filed for its US IPO and dosed the first patient in the trial in April, and it is now receiving initial results. This could explain a recent increase in their share price on the London Stock Exchange by […]

September 7, 2017 - 2 minutesmins - By Alex Dale

Circassia pharmaceuticals astrazeneca pulmonary disease

News and Trends 7 Sep 2017

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

Circassia has positive Phase III results from its respiratory pipeline, great news for the company after abandoning its allergy immunotherapies due to clinical failure. Circassia Pharmaceuticals, based in Oxford, has reported a Phase III success with Duaklir, a drug combination for the treatment of chronic obstructive pulmonary disease (COPD). The trial was run by AstraZeneca, […]

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Sep 2017

Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment

Tiziana makes moves towards a €37B market with an oral monoclonal antibody (mAb) formulation to treat non-alcoholic steatohepatitis (NASH) . Tiziana, which has previously developed compounds targeting the second most deadly form of cancer, has produced a novel formulation of the anti-CD3 mAb, Foralumab. The biologic will be tested in patients with NASH and other […]

September 6, 2017 - 3 minutesmins - By Alex Dale

Bicycle Therapeutics Bioverativ Hemophilia blood disorders

News and Trends 6 Sep 2017

A €344M Partnership will Develop Bicycle Drugs for Hemophilia

Bicycle Therapeutics has partnered with Bioverativ to develop a new class of drugs for patients with rare blood disorders like hemophilia and sickle cell disease. Bicycle Therapeutics, a money-magnet biotech founded by Greg Winter, has closed a deal with US firm Bioverativ for the discovery, development and commercialization of bicycle drugs for rare blood disorders. […]

September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

New British Biotech Enters the Clinic with Opioid Alternative for Chronic Pain

Could Using Bacteria’s Own Killing Capacity be a Knockout Blow in the Fight Against Antibiotic Resistance?

British Biotech Receives €52M Boost To Beat Antimicrobial Resistance with New Antibiotic

GSK wants in on Adaptimmune’s Adaptable T cell Cancer Treatment

Scottish Oncology Biotech Aims for €96M IPO in the Nasdaq

Verona Achieves Successful Results for Phase IIa Trial of Deadly Lung Disease Drug

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

Tiziana‘s Antibody Formulation Enters Phase IIa Trial for Liver Disease Treatment

A €344M Partnership will Develop Bicycle Drugs for Hemophilia

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!